Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 7, 2000, Pages 807-817

  Eriksson, Tommy ^a   Björkman, Sven ^a   Roth, Bodil ^a   Höglund, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; THALIDOMIDE DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHIRALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; ENANTIOMER; HUMAN; IMMUNOMODULATION; INFLAMMATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; TREATMENT OUTCOME;

EID: 0343627976     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001774660     Document Type: Article

References (36)

1. Atra, E., Sato, E. I. (1993) Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin. Exp. Rheumatol. 11: 487-493
2. Boughton, B. J., Sheehan, T. M. T., Wood, J., O'Brien, D., Butler, M., Simpson, A., Hale, K. A. (1995) High-performance liquid Chromatographic assay of plasma thalidomide: stabilization of specimens and determination of tentative therapeutic range for chronic graft-versus-host disease. Ann. Clin. Biochem. 32: 79-83
3. Chen, T.-L., Vogelsang, G. B., Petty, B. G., Brundrett, R. B., Noe, D. A., Santos, G. W., Colvin, O. M. (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metabol. Disp. 17: 402-405
4. Ebling, W. F., Jusko, W. J. (1986) The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits. J. Pharmacokin. Biopharm. 14: 557-599
5. Eriksson, T., Björkman, S. (1997) Handling of blood samples for determination of thalidomide. Clin. Chem. 43: 1094-1095
6. Eriksson, T., Björkman, S., Fyge, Å., Ekberg, H. (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J. Chromatogr. 582: 211-216
7. Eriksson, T., Björkman, S., Roth, B., Fyge, A., Höglund, P. (1995) Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7: 44-52
8. Eriksson, T., Björkman, S., Roth, B., Fyge, A., Höglund, P. (1998) The enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10: 223-228
9. Figg, W. D., Raje, S., Bauer, K. S., Tompkins, A., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J., Reed, E. (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci. 88: 121-125
10. Godfrey, K. R., Chapman, M. J. (1989) The problem of model indistinguishability in pharmacokinetics. J. Pharmacokin. Biopharm. 17: 229-267
11. Hague, D., Smith, R. L. (1988) Enigmatic properties of (±)-thalidomide; an example of a stable racemic compound. Br. J. Clin. Pharmacol. 26: 623P
12. Hamuryudan, V., Mat, C., Saip, S., Özyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K., Yazici, H. (1998) Thalidomide in the treatment of mucocutaneous lesions of the Behçet syndrome. Ann. Intern. Med. 128: 443-495
13. Heinzel, G., Wolf, V. G., Koss, F. W., Bozler, G. (1977) Modellentwicklung in der Pharmakokinetik. IV. Teil: Die Ermittlung der Mikrokonstanten in linearen Kompartmentmodellen. Arzneim. Forsch. 27: 912-931
14. Heney, D., Norfolk, D. R., Wheeldon, J., Bailey, C. C. Lewis, I. J., Barnard, D. L. (1991) Thalidomide treatment for chronic graft-versus-host disease. Br. J. Haematol. 78: 23-27
15. Höglund, P., Eriksson, T., Björkman, S. (1998) A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokin. Biopharm. 26: 363-383
16. Jacobson, J. M. Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., Vasquez, G. J., Wohl, D. A. (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J. Med. 336: 1487-1493
17. Jacobson, J. M., Spritzler, J., Fox, L., Fahey, J. L., Jackson, J. B., Chernoff, M., Wohl, D. A., Wu, A. W., Hooton, T. M., Sha, B. E., Shikuma, C. M., MacPhail, L. A., Simpson, D. M., Trapnell, C. B., Basgoz, N. (1999) Thalidomide for the treatment of esophageal aphtous ulcers in patients with human immunodeficiency virus infection. J. Infect. Dis. 180: 61-67
18. Knoche, B., Blaschke, G. (1994) Investigations on the in vitro racemization of thalidomide by HPLC. J. Chromatogr. A 666: 235-240
19. Koch, H. P. (1984) Thalidomide and congeners as anti-inflammatory agents. Prog. Medicinal Chem. 22: 165-242
20. Krenn, M. Gamcsik, M. P., Vogelsang, G. B. Colvin, O. M., Leong, K. W. (1992) Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin. J. Pharm. Sci. 81: 685-689
21. Matis, J. H., Wehrly, T. E., Gerald, K. B. (1985) Use of residence time moments in compartmental analysis. Am. J. Physiol. 249: E409-E415
22. Nightingale, S. L. (1998) Thalidomide approved for erythema nodosum leprosum. J. Am. Med. Assoc. 280: 872
23. Nishimura, K., Hashimoto, Y., Iwasaki, S. (1994) (S)-form of α-methyl-N(α)-phthalimido-glutarimide, but not its (R)-form, enhances phorbol ester-induced tumour necrosis factor-α production by human leukaemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull. 42: 1157-1159
24. Noormohamed, F. H., Youle, M. S., Higgs, C. J., Kook, K. A., Hawkins, D. A., Lant, A. F., Thomas, S. D. (1999) Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. Aids Res. Hum. Retroviruses 15: 1047-1052
25. Piscitelli, S. C., Figg, W. D., Hahn, B., Kelly, G., Thomas, S., Walker, R. E. (1997) Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 41: 2797-2799
26. Reist, M., Carrupt, P.-A., Francotte, E., Testa, B. (1998) Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11: 1521-1528
27. Schmidt, H., Rush, B., Simonian, G., Murphy, T., Hsieh, J., Condon, M. (1996) Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats. J. Surg. Res. 63: 143-146
28. Schuler, S., Ehninger, U. (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 12: 364-369
29. Schumacher, H., Smith, R. L., Williams, R. T. (1965) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25: 324-337
30. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Barlogie, B. (1999)Antitumor activity of thalidomide in refractory multiple myeloma. N. Eng. J. Med. 341: 1565-1571
31. Trapnell, C. B., Donahue, J. M. Collins, S. R., Flockhart, D. A., Thacker, D., Abernethy, D. R. (1998) Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin. Pharmacol. Ther. 64: 597-602
32. Veng-Pedersen, P. (1978) General treatment of linear pharmacokinetics. J. Pharm. Sci. 67: 187-191
33. Westerling, D., Frigren, L., Höglund, P. (1993) Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. Ther. Drug Monit. 15: 364-374
34. Wnendt, S., Finkam, M., Winter, W., Ossig, J., Raabe, G., Zwingenberger, K. (1996) Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues. Chirality 8: 390-396
35. Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamonte, V., Beschorner, W. E., Jabs, D. A., Corio, R. L., Levin, L. S., Colvin, O. M., Wingard, J. R., Santos, G. W. (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326: 1055-1058
36. Zwingenberger, K., Wnendt, S. (1996) Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J. Inflamm. 46: 177-211